1) Vaccines do provide higher and longer protection than you get from infection alone
2) The incremental benefit of vaccines over prior infection alone is particularly obvious if you had COVID >1 year ago.
But it is also seen if Covid infection was less than a year ago.
3. Prior Covid infection has 80% efficacy in preventing Covid compared to no prior Covid infection. But this efficacy drops to 70% if the Covid infection was over a year ago.
Vaccines increase both numbers. They help both.
4. The study also shows vaccine efficacy decreases over time, especially after 6 months.
We know that now from many other studies. That's why boosters are important.
Get boosted.
5. Just like efficacy of vaccines goes down with time, efficacy of prior infection immunity also goes down with time. This study shows that after one year protection goes down. This is important.
It emphasizes the need for vaccines even if you have had prior Covid.
6. This study did not look at efficacy against severe disease and deaths. That's where we have really seen the marked effect of vaccines.
So whatever extra benefit you see in this study, double that. That's the benefit that's likely with vaccines against those endpoints. IMO.
7. Vaccines were developed in a tearing hurry in the midst of an unprecedented pandemic. So yes, the optimal interval and optimal number of doses were not established. We now know boosters are needed. That's the reality. It doesn't take away the remarkable benefit from vaccines.
Here is the thread I had written in Oct 2021 where I argued why vaccines will help even if you had prior Covid.
Here is a link to the thread that shows how vaccines continue to demonstrate efficacy against the omicron variant also. This is remarkable considering the omicron variant has so many mutations and the vaccines were developed against the wild type strain in 2020.
People may not realize that for some meds in the US, the money you pay as insurance copay/coinsurance may be higher than what you can get paying out of pocket without using insurance.
It's one of the mind boggling things about prescription drug prices.
Not even people in healthcare know.
A friend who works in healthcare commented that after I told him about the way meds are priced, he's now saving $1200 a year on just one medicine.
I hate to say this. But even as cases and deaths fall, COVID is not over: Get boosted. It is critical. Thread.
1/ In August last year, Malta became one of the highest vaccinated countries in the world. As cases rose with omicron, we thought deaths will stay low. They didn't.
2/ What happened? Did vaccines not work? Did the protection fade with time?
Well, we now know that vaccine efficacy after first 2 doses does go down with time. Malta raced to get everyone vaccinated. But when omicron hit, the population was >6 months out from initial vaccination
3/ Malta did recognize the importance of boosters early and offered them. But not everyone came and got the booster. There was also the small group of people who remained fully unvaccinated.
The beauty of Twitter in academic medicine is you can give an online lecture that reaches many times more people than you may reach even at a huge Plenary session.
However, impact on whether you actually influence clinical practice depends a lot on credibility. #MedTwitter
Academics should view Twitter as essential as original research papers, reviews, editorials, and lectures in terms of disseminating information that they think can help others in the field. #MedTwitter
If you make the time investment and interact with people in a friendly manner, you will reach people outside of your own circle. And ultimately help patients worldwide. #MedTwitter
89% reduction in risk of hospitalization or death. Oral therapy for 5 days in people at high risk of severe Covid. The graphs look impressive. nejm.org/doi/full/10.10…
I also like the succinct summary of competing treatments (molnupiravir, monoclonal antibodies, remdesivir) for the same patient population at the end of the discussion.
Puts the results of this trial in context.
Good discussion ins the editorial also about the trial, relative risk reduction vs absolute risk reduction. nejm.org/doi/full/10.10…
1/ Risk stratification: This is important both for counseling patients and to decide on treatment options. The more high risk factors, the higher the risk.
2/ Initial therapy. The 3 main choices are VRd, DRd, and Dara-VRd.
I prefer VRd. But the other options are reasonable. Transplant eligible patients need 3-4 cycles, then stem cell collection.
3/ Initial Therapy. For patients not eligible for transplant, results with DRd are outstanding. But it is more expensive and requires prolonged use of a triplet.